Log In Sign up
The largest database of trusted experimental protocols

Cd8 mab clone yts 169.4

Manufactured by BioXCell
Visit Supplier

CD8 mAb (clone YTS 169.4) is a monoclonal antibody that recognizes the CD8 cell surface antigen. It is a purified rat immunoglobulin G (IgG2b) antibody.

Automatically generated - may contain errors

Lab products found in correlation

Diphtheria toxin, by Merck Group (1 mentions) Cd154 mab clone mr1, by BioXCell (1 mentions) C57bl 6 b6 mice, by Charles River Laboratories (1 mentions) Pd l1 mab clone 10f 9g2, by BioXCell (1 mentions) Ipi145, by Active Motif (1 mentions) Wild type c57bl 6 mice, by Taconic Biosciences (1 mentions) Matrigel, by Bio-Techne (1 mentions) Nod scid il2rgammanull nsg mice, by Jackson ImmunoResearch (1 mentions)

Spelling variants of this product

YTS 169.4 (35 citations) CD8 (clone YTS 169.4, (8 citations) Clone YTS 169.4 (7 citations)

3 protocols using cd8 mab clone yts 169.4

1

CXCR4 Inhibitor and T-Cell Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
We purchased CXCR4i (AMD3100, Sigma-Aldrich); CD8 mAb (clone YTS 169.4), CD154 mAb (clone MR1) and murine CTLA4-Ig (BioXcell); diphtheria toxin (Sigma-Aldrich) and RPM (Sigma-Aldrich).
Wang L., Wang Z., Han R., Samanta A., Ge G., Levin L.S., Levine M.H, & Hancock W.W. (2020). Donor bone-marrow CXCR4+ Foxp3+ T-regulatory cells are essential for costimulation blockade-induced long-term survival of murine limb transplants. Scientific Reports, 10, 9292.
+ Open protocol
+ Expand
2

Murine Oral Cancer Tumor Induction

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Murine oral cancer (MOC) cells were provided by Dr. R. Uppaluri (Washington University School of Medicine) to our laboratory in 2014 and have been cultured as described (24 (link)). MOC cells were validated to be of epithelial origin (25 (link)), and routinely tested for mycoplasma. All experiments were approved by the NIDCD Animal Care and Use Committee. To establish MOC tumors, 5×106 MOC1 or 1×105 MOC2 cells were injected subcutaneously into the flank of wild-type (WT) C57BL/6 (B6) mice (Charles River). IPI-145 (Active Biochem) was administered via oral gavage daily for fourteen days. Control mice received oral gavage of vehicle (0.5% carboxymethylcellulose, 0.05% Tween 80 in ultra-pure water) alone. PD-L1 mAb (clone 10F.9G2, BioXCell), CD8 mAb (clone YTS 169.4), Ly6G mAb (clone 1A8) or isotype control antibody (clone LFT-2) treatments were performed via intraperitoneal (IP) injection (200 μg/injection).
Davis R.J., Moore E.C., Clavijo P.E., Friedman J., Cash H., Chen Z., Silvin C., Van Waes C, & Allen C. (2017). Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid derived suppressor cells with a selective inhibitor of PI3Kδ/γ. Cancer research, 77(10), 2607-2619.
+ Open protocol
+ Expand
3

Syngeneic and Xenograft Tumor Establishment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Wild-type C57BL/6 mice were purchased from Taconic and NOD-scid IL2Rgamma null (NSG) mice were purchased from Jackson Laboratories. Mice were housed in a pathogen free environment and all experiments were performed under an Animal care and Use Committee approved protocol. Syngeneic murine or xenograft human tumors were established by subcutaneous flank injection of tumor cells in Matrigel (Trevigen, 30% by volume). Mice were assessed for tumor growth three times weekly and tumor volume was calculated as: (length 2 x width)/2. In some experiments, CD8 cellular depletion was performed via intraperitoneal (IP) injection of a CD8 mAb (clone YTS 169.4, BioXCell).
Robbins Y., Greene S., Friedman J., Clavijo P.E., Waes C.V., Fabian K.P., Padget M., Sater H.A., Lee J.H., Soon‐Shiong P., Gulley J.L., Schlom J., Hodge J.W., & Allen C. (2020). Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!